Document text
Principal Investigator: Kenneth C Bagley
Organization: ORLANCE, INC.
Fiscal Year: 2021
Award: $955,395
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
In response to the emerging COVID-19 (SARS-CoV-2) pandemic, this supplement proposal to R44 AI138733-
01 will leverage our cutting-edge nucleic acid vaccine strategies, some of which that were developed under this
parent grant. Here, we request supplement funding to develop candidate COVID-19 DNA and RNA vaccines
expressing optimally designed immunogens for the SARS-CoV-2 spike protein. Nucleic acid (DNA and RNA)
vaccines offer significant promise for providing a rapid response solution to emerging infectious diseases
because only a partial genetic sequence of the pathogen is needed to generate a new vaccine. Following in vivo
delivery, DNA and RNA vaccines lead to in situ production of antigens, negating the need for a complex
manufacturing and process development required for purified recombinant protein, inactivated or live attenuated
vaccines. Nucleic acids can also be manufactured at low cost and are very stable at room temperature
eliminating the need for a cold chain. This provides a significant savings in the time needed to advance a new
vaccine from identification of genetic sequence to clinical testing and distribute it to the population. In addition,
possibly due to the ability of nucleic acid vaccines to present antigens in their natural conformation in vivo,
antibody responses are generally of higher avidity and broader specificity when compared to antibody induced
by subunit protein vaccines. Further, the intracellular expression of antigens also induces robust T cell responses
including potent CD8+ T cell responses that can more broadly recognize different viral strains and mediate
protection via enhanced clearance of the infection. Our approach will compare our optimized DNA and RNA
vaccine platform technologies alone and in combinations to identify a lead approach that induces the highest
and most rapid development of protective levels of neutralizing antibody after a single administration. In addition,
since nucleic acid vaccines tested in our lab have been shown to induce antibody and/or T cell responses that
induce cross-protective immunity in our universal influenza vaccine studies under our parent grant, we will
determine if the candidate vaccines exhibit cross reactivity against other coronavirus strains for broader
protection against future coronavirus strains with epidemic or pandemic potential. Our Aims include: Aim 1-
Design and compare immunogenicity of candidate SARS-CoV-2 DNA and RNA vaccines. Aim 2 - Maximize
immunogenicity of nucleic acid vaccines and rapid manufacture by combining DNA and replicon mRNA vaccines
together or with recombinant protein and optimizing DNA and mRNA formulations. Aim 3 - Safety and
immunogenicity of the lead COVID-19 nucleic acid ± protein vaccine in the preclinical nonhuman primate model.
If successful, should identify a lead candidate COVID-19 nucleic acid vaccine for phase I human clinical trials.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><Adjuvant><Antibodies><Antibody Response><Antigens><Attenuated Vaccines><Avidity><Biolistics><Blood Chemical Analyses><Blood Chemical Analysis><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><CV-19><CV19><Cell Body><Cells><Clinical Evaluation><Clinical Testing><Clinical Trials><CoV-2><CoV2><Cold Chains><Complex><Coronaviridae><Coronavirus><DNA><DNA Vaccines><Deoxyribonucleic Acid><Development><Dose><Emerging Communicable Diseases><Emerging Infectious Diseases><Epidemic><Exhibits><Formulation><Funding><Future><Gene-Gun Technique><Genetic><Goals><Human><Immune response><Immunity><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><In Situ><Infection><Injections><Lead><Live-attenuated Vaccine><Lung><Lung Respiratory System><Mediating><Messenger RNA><Methods><Mice><Mice Mammals><Modality><Modeling><Modern Man><Molecular Configuration><Molecular Conformation><Molecular Stereochemistry><Mucosa><Mucosal Tissue><Mucous Membrane><Murine><Mus><Naked DNA Vaccines><Needles><Nucleic Acid Vaccines><Nucleic Acids><Pb element><Phase><Plasmids><Population><Production><Protein Subunits><Proteins><RNA vaccine><RNA-based vaccine><Recombinant DNA Vaccines><Recombinant Proteins><Regimen><Replication Unit><Replicon><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Savings><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Specificity><Standardization><T cell response><T8 Cells><T8 Lymphocytes><Technology><Temperature><Time><Vaccination><Vaccines><Viral><Virus><Wuhan coronavirus><base><blood chemistry><clinical development><clinical test><conformation><conformational state><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><cost><cross reactivity><design><designing><develop a vaccine><development of a vaccine><developmental><evaluate vaccines><experiment><experimental research><experimental study><gene gun><hCoV19><heavy metal Pb><heavy metal lead><host response><immune system response><immunogen><immunogenicity><immunoresponse><in vivo><lead candidate><live vaccine><live vaccines><mRNA><mRNA vaccine><mRNA-based vaccine><manufacturing process development><nCoV2><neutralizing antibody><new vaccines><next generation vaccines><non-human primate><nonhuman primate><novel><novel vaccines><nucleic acid-based vaccine><pandemic><pandemic disease><parent grant><pathogen><pre-clinical><preclinical><primate development><pulmonary><research clinical testing><response><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine against flu><universal vaccine against influenza><vaccination study><vaccination trial><vaccine candidate><vaccine development><vaccine evaluation><vaccine formulation><vaccine response><vaccine screening><vaccine study><vaccine testing><vaccine trial>